ClinicalTrials.Veeva

Menu
P

Pillar Clinical Research | Bentonville, AR

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cariprazine
KarXT
BHV-7000
IXT-m200
MK-8189
JZP385
NMRA-335140
BIIB104
MK-8189-008
LB-102

Parent organization

This site is a part of Pillar Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 18 total trials

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.

Enrolling
Bipolar Disorder
Drug: Placebo
Drug: BHV-7000

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.

Invitation-only
Bipolar Disorder
Drug: BHV-7000

The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizop...

Enrolling
Bipolar I Disorder
Schizophrenia
Drug: Cariprazine Flexible Dose

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult...

Active, not recruiting
Schizophrenia
Drug: LB-102

Trial sponsors

AbbVie logo
Biohaven logo
Cerevel Therapeutics logo
Karuna Therapeutics logo
Biogen logo
B
B
C
I
Jazz Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems